Abstract
The number of protein folds in nature is limited, thus is not surprising that proteins with the same fold are able to exert different functions. The cysteine protease inhibitors that adopt an immunoglobulin- like fold (Ig-ICPs) are inhibitors encoded in bacteria and protozoan parasites. Structural studies indicate that these inhibitors resemble the structure of archetypical proteins with an Ig fold, like antibodies, cadherins or cell receptors. The structure of Ig-ICPs from four different protozoan parasites clearly shows the presence of three loops that form part of a protein-ligand interaction surface that resembles the antigen binding sites of antibodies. Thus, Ig-ICPs bind to different cysteine proteases using a tripartite mechanism in which their BC, DE and FG loops are responsible for the main interactions with the target cysteine protease. Ig-ICPs from different protozoan parasites regulate the enzymatic activity of host or parasite's proteases and thus regulate virulence and pathogenesis.
Keywords: Immunoglobulin fold, evolution, cysteine protease inhibitors, cysteine proteases, parasites, pathogenesis.
Graphical Abstract
Current Protein & Peptide Science
Title:Cysteine Proteases Inhibitors with Immunoglobulin-Like Fold in Protozoan Parasites and their Role in Pathogenesis
Volume: 18 Issue: 10
Author(s): Pedro Jimenez-Sandoval, Laura Margarita Lopez-Castillo, Carlos H. Trasviña-Arenas and Luis G. Brieba*
Affiliation:
- Laboratorio Nacional de Genómica para la Biodiversidad, Centro de Investigación y de Estudios Avanzados del IPN, Apartado Postal 629, CP 36821, Irapuato, Guanajuato,Mexico
Keywords: Immunoglobulin fold, evolution, cysteine protease inhibitors, cysteine proteases, parasites, pathogenesis.
Abstract: The number of protein folds in nature is limited, thus is not surprising that proteins with the same fold are able to exert different functions. The cysteine protease inhibitors that adopt an immunoglobulin- like fold (Ig-ICPs) are inhibitors encoded in bacteria and protozoan parasites. Structural studies indicate that these inhibitors resemble the structure of archetypical proteins with an Ig fold, like antibodies, cadherins or cell receptors. The structure of Ig-ICPs from four different protozoan parasites clearly shows the presence of three loops that form part of a protein-ligand interaction surface that resembles the antigen binding sites of antibodies. Thus, Ig-ICPs bind to different cysteine proteases using a tripartite mechanism in which their BC, DE and FG loops are responsible for the main interactions with the target cysteine protease. Ig-ICPs from different protozoan parasites regulate the enzymatic activity of host or parasite's proteases and thus regulate virulence and pathogenesis.
Export Options
About this article
Cite this article as:
Jimenez-Sandoval Pedro, Lopez-Castillo Margarita Laura, Trasviña-Arenas H. Carlos and Brieba G. Luis*, Cysteine Proteases Inhibitors with Immunoglobulin-Like Fold in Protozoan Parasites and their Role in Pathogenesis, Current Protein & Peptide Science 2017; 18 (10) . https://dx.doi.org/10.2174/1389203717666160813163837
DOI https://dx.doi.org/10.2174/1389203717666160813163837 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Geriatric Evaluation of Oncological Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Peptide Nucleic Acid Conjugates: Synthesis, Properties and Applications
Current Topics in Medicinal Chemistry New Immunosuppressants: Immunosuppression and Immunomodulation
Medicinal Chemistry Reviews - Online (Discontinued) Germinal and Somatic Trisomy 21 Mosaicism: How Common is it, What are the Implications for Individual Carriers and How Does it Come About?
Current Genomics Aging, Cancer, and Longevity: The Uncertain Road
Current Aging Science The In Vitro and In Vivo Inhibitory Effect of Dehydroaltenusin: A Specific Inhibitor of Mammalian DNA Polymerase α
Current Bioactive Compounds Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy
Mini-Reviews in Medicinal Chemistry Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm. Efficacy and Critical Aspects in Cell Therapy
Current Pharmaceutical Design Next Generation Sequencing in Non-Small Cell Lung Cancer: New Avenues Toward the Personalized Medicine
Current Drug Targets Fc Receptors as Potential Targets for the Treatment of Allergy, Autoimmune Disease and Cancer
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Quinoxalinone as a Privileged Platform in Drug Development
Mini-Reviews in Medicinal Chemistry Predicting Drug Metabolism Induction In Silico
Current Topics in Medicinal Chemistry Electrochemical Investigation on the Interaction Between Colchicine and DNA
Current Physical Chemistry OX40 and OX40L Interaction in Cancer
Current Medicinal Chemistry Emerging Technologies for Improving Bioavailability of Polyphenols
Current Nutrition & Food Science Epigenetic Modulation: A Promising Avenue to Advance Hematopoietic Stem Cell-Based Therapy for Severe Autoimmune Disorders
Epigenetic Diagnosis & Therapy (Discontinued) Anti-atherosclerotic Effects of Spice-Derived Phytochemicals
Current Medicinal Chemistry Combinations of Plant Polyphenols & Anti-Cancer Molecules: A Novel Treatment Strategy for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Hematopoietic Transplants for Disease Suppression and Cure in Type 1 Diabetes
Current Stem Cell Research & Therapy Salen Mn Complexes are Superoxide Dismutase/Catalase Mimetics that Protect the Mitochondria
Current Inorganic Chemistry (Discontinued)